Where research is often designed around scientific potential, the Dutch CardioVascular Alliance (DCVA) will organise special attention on valorisation. Doing so, consortia can develop more new products, technologies and methods that help lower cardiovascular disease burden and they can realise them faster. The alliance offers inspiration, expertise and funding through valorisation fast tracks from idea to company.
Researchers are inspired to valorise. The alliance will pro-actively create awareness about the future potential of applications through challenging and discussing research outcomes with relevant experts, such as entrepreneurs and investors. These experts will help identify opportunities, leverage their network and help evaluate concrete initiatives.
The alliance also helps to develop thematic technology transfer teams for cardiovascular research between universities. The team is a specialised point of contact for researchers, and build expertise by regularly sharing insights.
An important achievement is the launch of the FIRST fund.
FIRST is a joint early phase investment fund of the Dutch CardioVascular Alliance (DCVA) and Regenerative Medicine Crossing Borders (RegMed XB) with a total volume of 9.5 million euros. This initiative is important for Dutch patients, because of the gap that is still often found in translating results from fundamental medical research into available solutions, such as a new treatment or innovative technology. FIRST finances the first development into an "investment-ready" company based on proposals of sufficient quality and potential.More about the FIRST fundMore information about Valorisation (in Dutch)
The complete valorisation team, including the RegMedXB-part of the FIRST fund:
- Rob de Ree (DCVA)
- Marianne van der Steen (RegMed XB)
- Rianne Ellenbroek (BioGeneration Ventures)
- Margien Boels (DCVA)
- Luc Schoppink (DCVA)